Which has the lower trailing P/E, NUTX or OMCL?

NUTX has the lower trailing P/E: NUTX trades at 8.84 and OMCL at 41.64. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, NUTX or OMCL?

Over the past five years, NUTX grew revenue faster — NUTX at a 37.66% CAGR versus OMCL at 4.77%.

Is NUTX or OMCL more profitable?

NUTX runs the higher net margin — NUTX at 21.25% versus OMCL at 3.13%.

How have NUTX and OMCL total returns compared?

Over the past 10 years, NUTX delivered -27.99% and OMCL delivered -0.80% annualized total return. Past performance doesn't predict future results.

Nutex Health, Inc. (NUTX) vs Omnicell, Inc. (OMCL)

A side-by-side comparison of Nutex Health, Inc. and Omnicell, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

NUTX

Nutex Health, Inc.

$1.54B

$223.38HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT

OMCL

Omnicell, Inc.

$1.60B

$35.18HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT

Total return — NUTX vs OMCL

growth of $100 · dividends reinvested · last 10y

NUTX -90.0% (-20.6%/yr)OMCL -6.6% (-0.7%/yr)OMCL compounded faster over this window

Log scale — wide-divergence pair

NUTX OMCL

NUTX vs OMCL: by the numbers

•OMCL is the larger company ($1.60B vs $1.54B market cap).
•NUTX trades at the lower trailing earnings multiple (8.84 vs 41.64 P/E), one valuation lens rather than an overall verdict.
•NUTX converts more revenue to profit (21.25% vs 3.13% net margin).
•NUTX grew revenue faster over the past five years (37.66% vs 4.77% CAGR).

Metrics side by side

Valuation

Metric	NUTX	OMCL
P/E ratio	8.84	41.64
Forward P/E	8.04	15.51
P/S ratio	1.82	1.28
P/B ratio	3.90	1.24
EV / EBITDA	4.36	10.66
FCF yield	17.84%	8.84%

Profitability

Metric	NUTX	OMCL
Gross margin	51.26%	44.77%
Operating margin	31.49%	4.73%
Net margin	21.25%	3.13%
ROE	45.63%	3.03%
ROIC	33.76%	2.43%

Growth (annualized)

Metric	NUTX	OMCL
Revenue CAGR (5Y)	37.66%	4.77%
EPS CAGR (5Y)	-14.73%	-43.29%
FCF CAGR (5Y)	N/A	-8.10%
Total return CAGR (5Y)	-18.99%	-26.44%

Frequently asked

Which has the lower trailing P/E, NUTX or OMCL?: NUTX has the lower trailing P/E: NUTX trades at 8.84 and OMCL at 41.64. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, NUTX or OMCL?: Over the past five years, NUTX grew revenue faster — NUTX at a 37.66% CAGR versus OMCL at 4.77%.
Is NUTX or OMCL more profitable?: NUTX runs the higher net margin — NUTX at 21.25% versus OMCL at 3.13%.
How have NUTX and OMCL total returns compared?: Over the past 10 years, NUTX delivered -27.99% and OMCL delivered -0.80% annualized total return. Past performance doesn't predict future results.

Go deeper

Full NUTX analysis Full OMCL analysis Interactive comparison tool

Dig into the metrics

Nutex Health P/E ratio Omnicell P/E ratio Nutex Health ROE Omnicell ROE Nutex Health operating margin Omnicell operating margin Nutex Health revenue growth Omnicell revenue growth Nutex Health free cash flow Omnicell free cash flow

Nutex Health & Omnicell appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest ROIC Stocks Highest Operating Margin Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.